# MEVPRO-1 (NCT06551324)

> A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06551324
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Interventions: PF-06821497; Docetaxel; Enzalutamide
- Enrollment: 600
- Primary outcome: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 31
- YouTube: 7
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=mevpro-1-nct06551324

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06551324", "email": "<work email>"}; the inbox owner confirms by the emailed link.